吉非替尼联合化疗方案对EGFR突变晚期非小细胞肺癌患者疗效及CA19-9、CYFRA21-1、CEA表达的影响  

Influence of gefitinib combined with chemotherapy regimen on the efficacy and expression of CA19-9,CYFRA21-1 and CEA in patients with EGFR-mutated advanced non-small cell lung cancer

作　　者：刘爽 刘艳梅 曲佳哲 LIU Shuang;LIU Yan-mei;QU Jia-zhe(Department of Oncology,Fuxin diabetes Hospital(Beiyuan Branch),Fuxin 123000,China)

机构地区：[1]阜新市糖尿病医院(北院区)肿瘤内科,123000

出　　处：《中国实用医药》2023年第3期106-108,共3页China Practical Medicine

摘　　要：目的探究吉非替尼联合化疗方案对表皮生长因子(EGFR)突变晚期非小细胞肺癌患者的临床疗效。方法80例EGFR突变晚期非小细胞肺癌患者,按照住院顺序分为对照组和观察组,各40例。对照组采用常规化疗方案治疗,观察组在对照组的基础上增加吉非替尼干预治疗。对比两组患者治疗前后卡氏功能状态评分(KPS)及肿瘤相关指标[糖类抗原CA19-9(CA19-9)、细胞角蛋白19片段(CYFRA21-1)及癌胚抗原(CEA)]。结果治疗后,观察组KPS评分(87.73±5.55)分高于对照组的(83.54±5.65)分,差异有统计学意义(P<0.05)。治疗后,观察组CA19-9、CYFRA21-1及CEA水平分别为(32.17±5.66)U/ml、(2.77±0.88)ng/ml、(8.56±0.77)μg/L,均明显低于对照组的(35.54±5.21)U/ml、(3.34±0.98)ng/ml、(9.12±0.74)μg/L,差异有统计学意义(P<0.05)。结论吉非替尼联合化疗方案可有效改善EGFR突变晚期非小细胞肺癌患者CA19-9、CYFRA21-1及CEA的表达,进而提高化疗效果。Objective To investigate the clinical efficacy of gefitinib combined with chemotherapy regimen on patients with epidermal growth factor receptor(EGFR)-mutated advanced non-small cell lung cancer.Methods A total of 80 patients with EGFR-mutated advanced non-small cell lung cancer were divided into a control group and an observation group in the order of hospitalization,with 40 cases in each group.The control group was treated with conventional chemotherapy regimen,and the observation group was treated with additional gefitinib intervention on the basis of the control group.Both groups were compared in terms of Karnofsky performance scale(KPS)score and tumor-related indexes[carbohydrate antigen CA19-9(CA19-9),cytokeratin 19 fragment(CYFRA21-1)and carcinoembryonic antigen(CEA)]before and after treatment.Results After treatment,the KPS score(87.73±5.55)points of the observation group was higher than(83.54±5.65)points of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of CA19-9,CYFRA21-1 and CEA in the observation group were(32.17±5.66)U/ml,(2.77±0.88)ng/ml and(8.56±0.77)μg/L,which were significantly lower than(35.54±5.21)U/ml,(3.34±0.98)ng/ml and(9.12±0.74)μg/L in the control group,and the differences were statistically significant(P<0.05).Conclusion Gefitinib combined with chemotherapy regimen can effectively improve the expression of CA19-9,CYFRA21-1 and CEA in patients with EGFR-mutated advanced non-small cell lung cancer,thereby improving the chemotherapy effect.

关 键 词：吉非替尼 非小细胞肺癌 晚期 表皮生长因子突变 

分 类 号：R734.2[医药卫生—肿瘤]